Tlando is a drug owned by Verity Pharmaceuticals Inc. It is protected by 14 US drug patents filed from 2022 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2041. Details of Tlando's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11464735 | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(15 years from now) | Active |
| US12011503 | Fixed dose oral testosterone undecanoate compositions and use thereof |
Oct, 2040
(14 years from now) | Active |
| US12310978 | Composition and method for oral delivery of androgen prodrugs |
Feb, 2039
(13 years from now) | Active |
| US11559530 | Oral testosterone undecanoate therapy |
Nov, 2037
(12 years from now) | Active |
| US9943527 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US10716794 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US9949985 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US11364249 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US11433083 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US11311555 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US10226473 | High-strength testosterone undecanoate compositions |
Nov, 2030
(5 years from now) | Active |
| US8778922 | Steroidal compositions |
Jan, 2029
(3 years from now) | Active |
| US11304960 | Steroidal compositions |
Jan, 2029
(3 years from now) | Active |
| US8865695 | Steroidal compositions |
Jan, 2029
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Tlando's patents.
Latest Legal Activities on Tlando's Patents
Given below is the list of recent legal activities going on the following patents of Tlando.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 09 Mar, 2023 | US10226473 |
| Surcharge for late Payment, Small Entity | 09 Mar, 2023 | US10226473 |
| Recordation of Patent Grant Mailed
Critical | 24 Jan, 2023 | US11559530 |
| Patent Issue Date Used in PTA Calculation
Critical | 24 Jan, 2023 | US11559530 |
| Correspondence Address Change
Critical | 09 Jan, 2023 | US11464735 |
| Email Notification
Critical | 05 Jan, 2023 | US11559530 |
| Issue Notification Mailed
Critical | 04 Jan, 2023 | US11559530 |
| Mail Miscellaneous Communication to Applicant | 28 Dec, 2022 | US11559530 |
| Email Notification
Critical | 28 Dec, 2022 | US11559530 |
| Miscellaneous Communication to Applicant - No Action Count | 22 Dec, 2022 | US11559530 |
FDA has granted several exclusivities to Tlando. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Tlando, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Tlando.
Exclusivity Information
Tlando holds 1 exclusivities. All of its exclusivities have expired in 2025. Details of Tlando's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
US patents provide insights into the exclusivity only within the United States, but
Tlando is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tlando's family patents as well as insights into
ongoing legal events
on those patents.
Tlando's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tlando's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 28, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tlando Generics:
There are no approved generic versions for Tlando as of now.
Alternative Brands for Tlando
Tlando which is used for treating conditions associated with low levels of testosterone in adult males., has several other brand drugs in the same treatment category and using the same active ingredient (Testosterone Undecanoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Endo Operations |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Testosterone Undecanoate. Given below is the list of those drugs and companies owning them.
About Tlando
Tlando is a drug owned by Verity Pharmaceuticals Inc. It is used for treating conditions associated with low levels of testosterone in adult males. Tlando uses Testosterone Undecanoate as an active ingredient. Tlando was launched by Verity in 2022.
Approval Date:
Tlando was approved by FDA for market use on 28 March, 2022.
Active Ingredient:
Tlando uses Testosterone Undecanoate as the active ingredient. Check out other Drugs and Companies using Testosterone Undecanoate ingredient
Treatment:
Tlando is used for treating conditions associated with low levels of testosterone in adult males.
Dosage:
Tlando is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 112.5MG | CAPSULE | Prescription | ORAL |